JonesResearch initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $7 price target based on the firm’s view of the company’s “promising” pipeline of T cell engagers targeting solid tumors. The firm believes the pipeline has a potential probability-adjusted market opportunity of over $1B in 2037, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
- Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting
- Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright
- Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating
- Context Therapeutics Reports Improved Quarterly Results